Search

Displaying results 2921 - 2930 of 3387 in total
  1. Drug

    P-42 peptide

    go.drugbank.com/drugs/DB18610
    Experimental

    P-42 peptide is a synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein

  2. Drug

    Enavogliflozin

    go.drugbank.com/drugs/DB18970
    Investigational

    Enavogliflozin is under investigation in clinical trial NCT06399835 (Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Aminoflavone

    go.drugbank.com/drugs/DB19077
    Investigational

    Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  4. Drug

    Arketamine

    go.drugbank.com/drugs/DB19150
    Investigational

    Arketamine is under investigation in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and Efficacy of PCN-101 in TRD).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  5. Drug

    Substance P

    go.drugbank.com/drugs/DB19198
    Investigational

    Substance P is under investigation in clinical trial NCT03738878 (Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1).

    Synonyms: Substance P, Neurokinin pCategories: Substance P, antagonists & inhibitors
  6. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally … [L64094,L64107] It binds the ligand binding domain of ERα, antagonizing ERα encoded by both wild-type and mutated *ESR1* and inducing proteasome-dependent degradation of the receptor without agonizing

    Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor Degraders
  7. Drug

    Nafithromycin

    go.drugbank.com/drugs/DB16246
    Investigational

    Nafithromycin is under investigation in clinical trial NCT02903836 (Phase II Study of Oral Nafithromycin in CABP).

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  8. Drug

    Osalmid

    go.drugbank.com/drugs/DB16273
    Investigational

    Osalmid is under investigation in clinical trial NCT03670173 (Safety and Efficacy Assessments of Osalmid in Multiple Myeloma).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  9. Drug

    Vitis vinifera seed

    go.drugbank.com/drugs/DB16606
    Investigational

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  10. Drug

    Cepharanthine

    go.drugbank.com/drugs/DB16824
    Investigational

    Categories: P-glycoprotein inhibitors